RH109
/ Jiangsu Rec-Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
July 14, 2023
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Wuhan Rhegen Biotechnology Co., Ltd. | N=40 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease
April 27, 2023
Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Wuhan Recogen Biotechnology Co., Ltd. | N=24 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease
April 26, 2023
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Wuhan Rhegen Biotechnology Co., Ltd. | Trial completion date: Mar 2023 ➔ Dec 2023 | Initiation date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Mar 2023 ➔ Aug 2023
Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
November 08, 2022
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Wuhan Recogen Biotechnology Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease
May 09, 2022
Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Wuhan Recogen Biotechnology Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease
April 28, 2022
Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease
1 to 6
Of
6
Go to page
1